Green Pharmaceuticals from Lignin

acib_open_innovation-pn0gwbmnm7mep6gvfoep1yj3d1ipxdg4q1xmb83d78

Imagine a future, where pharmaceuticals are derived from wood waste, not petroleum ... Green and bio-based pharmaceuticals represent a paradigm shift in the pharma industry, where sustainability and eco-friendliness are paramount. By leveraging novel innovative approaches in green chemistry and biotechnology it is possible to deliver new therapeutic agents with a reduced ecological footprint. This holistic approach aligns with the growing global demand for sustainable solutions and is poised to create a treasure trove of renewable medicines for the future.

Background

The demand for sustainable and economically viable sources of pharmaceutical compounds is on the rise. Traditional methods rely heavily on petrochemicals, leading to environmental pollution and resource depletion. By utilizing lignin, a major component of biomass, as a starting material a greener approach to drug synthesis becomes possible. Lignin offers a rich source of aromatic compounds that can be transformed into complex pharmaceutical scaffolds, providing a renewable alternative to fossil-based precursors.

Technology

acib extends an exclusive opportunity to co-develop
  • Novel catalytic methods for the synthesis of pharmaceutical compounds from lignin-derived platform chemicals.
  • Identification of lead compounds with promising biological activity against infectious diseases, inflammation, and cancer.
  • Optimization of reaction conditions and solvent systems to enhance green chemistry metrics and process sustainability.
  • Demonstration of the economic feasibility and scalability of the proposed synthetic routes, contributing to the advancement of lignin valorization and biorefinery processes.

Offer

acib extends an exclusive opportunity to co-develop

  • Novel catalytic methods for the synthesis of pharmaceutical compounds from lignin-derived platform chemicals.
  • Identification of lead compounds with promising biological activity against infectious diseases, inflammation, and cancer.
  • Optimization of reaction conditions and solvent systems to enhance green chemistry metrics and process sustainability.
  • Demonstration of the economic feasibility and scalability of the proposed synthetic routes, contributing to the advancement of lignin valorization and biorefinery processes.

Intellectual property (IP) generated in this project seamlessly transfers to you, our investor/industrial partner. Take the lead in spearheading the future of sustainable and cost-effective bio-based pharmaceutical production with acib!

Experts:

Prof. Dr. Katalin Barta-Weissert, Dr. Markus Hochegger

Development status:

TRL 4 (Technology validated in lab)

Keywords:

Bio-based pharmaceuticals, Sustainable production, Active pharmaceutical ingredients (APIs), Green Chemistry Platform, Chemicals Anti-Infectives, Renewable Resources, Circular Economy

Dr. Martin U. Trinker
Director Business Development & Fundraising
Krenngasse 37
8010 Graz
e-mail
+43 316 873 9316